[go: up one dir, main page]

NO20000935L - Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei - Google Patents

Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei

Info

Publication number
NO20000935L
NO20000935L NO20000935A NO20000935A NO20000935L NO 20000935 L NO20000935 L NO 20000935L NO 20000935 A NO20000935 A NO 20000935A NO 20000935 A NO20000935 A NO 20000935A NO 20000935 L NO20000935 L NO 20000935L
Authority
NO
Norway
Prior art keywords
alternative pathway
complement activation
activation via
inhibiting complement
inhibiting
Prior art date
Application number
NO20000935A
Other languages
English (en)
Other versions
NO20000935D0 (no
Inventor
Rekha Gupta-Bansal
Kurt R Brunden
James B Parent
Original Assignee
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliatech Inc filed Critical Gliatech Inc
Publication of NO20000935D0 publication Critical patent/NO20000935D0/no
Publication of NO20000935L publication Critical patent/NO20000935L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cereal-Derived Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • External Artificial Organs (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20000935A 1997-08-26 2000-02-25 Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei NO20000935L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26
PCT/US1998/017500 WO1999010009A1 (en) 1997-08-26 1998-08-24 A process for inhibiting complement activation via the alternative pathway

Publications (2)

Publication Number Publication Date
NO20000935D0 NO20000935D0 (no) 2000-02-25
NO20000935L true NO20000935L (no) 2000-04-18

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000935A NO20000935L (no) 1997-08-26 2000-02-25 Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei

Country Status (13)

Country Link
US (3) US6333034B1 (no)
EP (1) EP1007092B1 (no)
JP (1) JP2001513576A (no)
AT (1) ATE335511T1 (no)
AU (1) AU756490B2 (no)
CA (1) CA2302317A1 (no)
DE (1) DE69835524T2 (no)
DK (1) DK1007092T3 (no)
ES (1) ES2270530T3 (no)
NO (1) NO20000935L (no)
NZ (1) NZ503033A (no)
PT (1) PT1007092E (no)
WO (1) WO1999010009A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
WO2003009803A2 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
WO2005094880A1 (en) * 2004-03-30 2005-10-13 Canadian Blood Services Method for treating autoimmune diseases with antibodies
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2610340C (en) * 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
ES2831325T3 (es) 2006-10-10 2021-06-08 Regenesance B V Inhibición del complemento para una mejor regeneración de los nervios
CL2007003161A1 (es) * 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
WO2011109494A2 (en) * 2010-03-02 2011-09-09 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
US20100263061A1 (en) * 2007-06-11 2010-10-14 The Trustees Of The University Of Pennsylvania Properdin Modulation of Alternative Pathway and Uses Thereof
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
CN101970002B (zh) * 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
EP2262831B1 (en) * 2008-03-03 2015-01-21 NovelMed Therapeutics, Inc. Anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010030789A1 (en) * 2008-09-10 2010-03-18 Novelmed Therapeutics, Inc. Device and method for inhibiting complement activation
US20110262456A1 (en) * 2008-11-14 2011-10-27 Rekha Bansal Method of treating ischemia reperfusion injury
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2545075B1 (en) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
WO2013152024A1 (en) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor c3 antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation

Also Published As

Publication number Publication date
EP1007092A1 (en) 2000-06-14
US20020015701A1 (en) 2002-02-07
ATE335511T1 (de) 2006-09-15
DE69835524T2 (de) 2007-04-05
US20030198636A1 (en) 2003-10-23
AU756490B2 (en) 2003-01-16
DK1007092T3 (da) 2006-10-02
ES2270530T3 (es) 2007-04-01
DE69835524D1 (de) 2006-09-21
EP1007092B1 (en) 2006-08-09
WO1999010009A1 (en) 1999-03-04
CA2302317A1 (en) 1999-03-04
AU9203398A (en) 1999-03-16
NO20000935D0 (no) 2000-02-25
NZ503033A (en) 2003-01-31
US6333034B1 (en) 2001-12-25
PT1007092E (pt) 2006-12-29
JP2001513576A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
NO20000935L (no) Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
NO975387L (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
BG101833A (bg) Гуаниново производно
BG102474A (en) (-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
IS4147A (is) Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
NO971645L (no) Fremgangsmåte for fremstilling av derivater av 4a,5,9,10,11,12,-heksahydro-6H-benzofuro£3a,3,2-ef|£2|-benzacepin
NO981800L (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
TR199601005A2 (tr) Uzun zincirli, dallanmis poliolefinlerin üretimi icin yöntem.
AU2895397A (en) Novel substance library and supramolecular complexes prepared therewith
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
BG103650A (en) Method for the preparation of eprosartan
FI960937A7 (fi) Menetelmä aryylialkyylihydroperoksidien valmistamiseksi
NO990450D0 (no) Behandling av sinnslidelser
NO974155L (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
PL356523A1 (en) Substituted 1 and 2 naphthol mannich bases
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
NO971550D0 (no) Fremgangsmåte for fremstilling av en tetning, samt pressinnretning
ZA995559B (en) Improved process for the production of an n-acyl derivative of O,S-dialkyl phosphoroamidothioate.
NZ310180A (en) Process for the synthesis of benzo[b]thiophenes, in particular 2-aryl-benzo[b]thiophenes
MX9604599A (es) Procedimiento para la sintesis enzimatica de nucleotido-6-desoxi-d-xilo-4-hexulosas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application